CD45 isoform alteration in CD4
View Patent ↗Methods for assessing the risk of developing Alzheimer's Disease (AD), for diagnosing AD, and for measuring the progression of AD in a patient by determining CD45 isoform expression of blood cells obtained from the patient. The methods of the invention include determining CD45 isoform expression by cytometric analysis, quantitative Western immunoblotting, or quantitative RT-PCR or combinations thereof.
1. A method of assessing the risk of developing and of diagnosing Alzheimer's disease in a patient comprising:
(i) obtaining a blood sample from a patient;
(ii) determining CD45RA and CD45RO expression of T cells contained in the blood sample; and
(iii) relating the determined CD45RA and CD45RO expression to an assessment of the risk of developing the disease or a diagnosis of the disease,
wherein a decreased CD45RO/RA expression and an increased CD45RO/RA ratio compared to control subjects indicates a risk of developing Alzheimer's disease or a diagnosis of Alzheimer's disease.
2. The method of claim 1 in which CD45RA and CD45RO expression is determined by cytometric analysis, Western blot, RT-PCR, or a combination thereof.
3. The method of claim 1 , which is directed to assessing the risk of developing the disease.
4. The method of claim 1 , which is directed to diagnosing the disease.
5. The method of claim 1 , further comprising:
determining an APOE ε4 genotype in a patient; and
relating the presence of the APOE ε4 genotype biomarker to the determined CD45RA and CD45RO expression in the patient, wherein the finding that the patient has the APOE ε4 genotype and has a decreased expression of CD45RA and an increased CD45RO/CD45RA ratio compared to control subjects increases the sensitivity, positive predictive value and negative predictive value of assessing the risk of developing and diagnosing Alzheimer's disease as compared to determining the APOE ε4 genotype of the patient alone.